Centessa Pharmaceuticals Reports <a href="https://laohu8.com/S/QTWO">Q2</a> 2025 Results: Net Loss Widens to $50.<a href="https://laohu8.com/S/MMM">3M</a>, Increased R&D Spending Highlights Focus on Orexin Agonist Pipeline
Centessa Pharmaceuticals plc has reported its financial results for the second quarter ending June 30, 2025. The company recorded a net loss of $50.3 million, an increase from the $43.8 million net loss in the same period of 2024. General and Administrative expenses rose to $11.9 million compared to $11.2 million the previous year, while Research and Development expenses increased significantly to $42.7 million from $32.8 million in the second quarter of 2024. Cash, cash equivalents, and investments totaled $404.1 million as of June 30, 2025, with the company projecting that these funds will support operations into mid-2027. Centessa Pharmaceuticals continues to advance its orexin receptor 2 (OX2R) agonist franchise, with key data readouts expected within the year. This includes the ORX750 Phase 2a CRYSTAL-1 study for narcolepsy and idiopathic hypersomnia and the ORX142 Phase 1 trial for select neurological disorders. ORX489 remains in IND-enabling studies for neuropsychiatric disorders.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Centessa Pharmaceuticals plc published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001847903-25-000133), on August 12, 2025, and is solely responsible for the information contained therein.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。